
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Insights from the AMCP Nexus 2025 Meeting
2
The Shift in Star Ratings That Health Plans Can't Ignore
3
Clinical and Economic Impact of OAB Symptoms in Men Receiving Pharmacological Treatment for BPH
4
MHE Week in Review – HPV Vaccine Still Effective, Dry Eye Disease Lacks Effective Treatments and More
5

















































